March 23 (Reuters) - MEI Pharma says its cancer drug failed to meet the main goal in a mid-stage study.
The drug, pracinostat, in combination with chemotherapy drug azacitidine showed no difference in complete remission in previously untreated patients with myelodysplastic syndrome (MDS) - a type of blood cancer - against azacitidine alone.
Complete remission implies the disappearance of all signs of cancer in response to treatment. It does not always constitute a cure.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty)